Immunic (IMUX) Q3 2024 earnings summary

Executive summary

• Strengthened management with new President/COO Jason Tardio, Chief Development Officer Werner Gladdines, and Board member Simona Skerjanec, enhancing commercialization and clinical operations expertise.

• Advanced lead asset vidofludimus calcium in multiple sclerosis with ongoing Phase 3 ENSURE trials in relapsing MS and Phase 2 CALLIPER trial in progressive MS, presenting positive interim data and biomarker results at major MS congresses.

• IMU-856 completed Phase 1b in celiac disease with significant clinical improvements; Phase 2 preparations underway, contingent on additional funding or partnerships.

• Initiated investigator-sponsored Phase 2 trial in post-COVID syndrome and continued partnering discussions for lead assets.

• Closed $80 million first tranche of a private placement in January 2024, with up to $240 million possible if future tranches are triggered.

Financial highlights

• Ended Q3 2024 with $59.1 million in cash and equivalents, expected to fund operations into Q3 2025.

• Q3 2024 net loss was $24.4 million ($0.24/share), compared to $22.8 million ($0.51/share) in Q3 2023; nine-month 2024 net loss was $75.3 million ($0.75/share), versus $72 million ($1.63/share) in the prior year.

• Q3 2024 R&D expenses were $21.4 million, up from $19.8 million in Q3 2023; G&A expenses rose to $4.4 million from $3.8 million.

• For the nine months ended September 30, 2024, R&D expenses decreased to $58.4 million from $63.9 million year-over-year, while G&A expenses increased to $14.0 million.

• Accumulated deficit reached $486.2 million as of September 30, 2024.

Outlook and guidance

• Top-line data from Phase 2 CALLIPER trial in progressive MS expected in April 2025, with comprehensive subgroup and biomarker analysis.

• Completion of first Phase 3 ENSURE trial in relapsing MS anticipated in Q2 2026, second in H2 2026.

• Preparing for Phase 2 clinical testing of IMU-856 in gastrointestinal disorders, pending additional funding or partnerships.

• Ongoing discussions with potential pharmaceutical partners for lead assets.

• Company expects continued significant expenses and increasing operating losses as it advances clinical programs and expands personnel.